A metaanalysis of 43 randomized clinical trials (in 11,281 patients) comparing ARBs with placebo, drugs in other antihy- pertensive classes, and other ARBs found comparable blood pres- sure reductions for all ARBs; response rates were 48% to 55% (1, 4). The results of these trials suggest that candesartan, irbesartan, and telmisartan be slightly more effective than losartan.